Study of RO7250284 in Participants With Neovascular Age-Related Macular Degeneration

  • Eye Disorder
  • Macular Degeneration
  • Age-Related Macular Degeneration
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • United States
Trial Identifier:

NCT04567303 BP41670

      Show trial locations

      The source of the below information is public registry websites such as,,, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to and/or and/or

      The below information is taken directly from public registry websites such as,,, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD)

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT04567303,BP41670 Trial Identifier
      Zifibancimig, Ranibizumab, Port Delivery Platform Treatments
      Macular Degeneration Condition
      Official Title

      A Three-Part, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-Related Macular Degeneration

      Eligibility Criteria

      All Gender
      ≥50 Years Age
      No Healthy Volunteers
      Inclusion Criteria

      Part 1, Part 2 and Part 3 Inclusion Criteria:

      • Willing to allow AH collection.

      Part 1 and Part 2 Ocular Inclusion Criteria for Study Eye:

      • Choroidal neovascularization (CNV) exclusively due to age-related macular degeneration (AMD).
      • Anti-vascular endothelial growth factor (VEGF) or anti-VEGF/Angiopoietin-2 (Ang-2) IVT treatment-naïve, or pre-treated with anti-VEGF or anti-VEGF/Ang-2 no less than two months prior to Day 1.
      • Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading by the central reading center of fundus photography (FP), fluorescein angiography (FA), fundus autofluorescence (FAF), and spectral domain optical coherence tomography (SD-OCT) images.
      • Decreased BCVA attributable primarily to nAMD, with BCVA letter score of 78 to 34 letters (inclusive) on ETDRS-like charts at screening. In case both eyes of a participant are eligible, the eye with the lower BCVA score should become the study eye.

      Part 3 Ocular Inclusion Criteria for Study Eye:

      • CNV exclusively due to AMD.
      • Diagnosis of nAMD within nine months prior to the screening visit.
      • Previous treatment with at least two IVT anti-VEGF or anti-VEGF/Ang-2 administrations IVT for nAMD. The last IVT administration must have occurred at least 21 days prior to the screening visit.
      • Demonstrated response to prior IVT anti-VEGF or anti-VEGF/Ang-2 treatment since diagnosis.
      • Availability of historical VA data prior to the first anti-VEGF or anti-VEGF/Ang-2 treatment for nAMD.
      • Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading.
      • Decreased BCVA attributable primarily to nAMD with letter score of 78 to 34 letters (inclusive) or better on ETDRS-like charts.
      Exclusion Criteria

      Exclusion Criteria for Study Eye:

      • History of vitrectomy surgery, submacular surgery, other intraocular surgery, or any planned surgical intervention during the study period.
      • Cataract surgery without complications within three months preceding the screening visit or planned during the study period.
      • Aphakia or absence of the posterior capsule. Previous violation of the posterior capsule is also an exclusion criterion, unless it occurred as a result of yttrium-aluminum garnet laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation.
      • Prior macular treatment with verteporfin, external beam radiation therapy, transpupillary thermotherapy, or any type of laser photocoagulation.
      • Prior treatment with IVT corticosteroids or implant (e.g., triamcinolone, ozurdex, iluvien).
      • Subretinal hemorrhage >50% of the total lesion area and/or involving the fovea.
      • Subfoveal fibrosis or subfoveal atrophy.
      • Retinal pigment epithelial tear involving the macula.
      • History of vitreous hemorrhage, rhegmatogenous retinal detachment, glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery, and corneal transplant.
      • History of rhegmatogenous retinal tears or peripheral retinal breaks within three months prior to the screening visit.
      • Actual or history of myopia >-8 diopters.
      • Uncontrolled ocular hypertension or glaucoma (defined as intraocular pressure (IOP) >25 millimeters of mercury (mm Hg) or a cup to disc ration >0.8, despite treatment with antiglaucoma medication) and any such condition the Investigator determines may require a glaucoma-filtering surgery during a participant's participation in the study.
      • Concurrent intraocular conditions (e.g., cataract, diabetic retinopathy, epiretinal membrane with traction, macular hole) that, in the opinion of the Investigator, could either:
      • Require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition; or
      • Likely contribute to loss of BCVA over the study period if allowed to progress untreated; or
      • Preclude any visual improvement due to substantial structural damage.
      • Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PD implant.
      • Prior treatment with any medication for geographic atrophy.
      • Prior treatment with any anti-VEGF-C or anti-VEGF-D inhibitors.

      Exclusion Criteria for Fellow Eye

      • BCVA letter score using ETDRS charts of < 34 letters.
      • Treatment with anti-VEGF or anti-VEGF/Ang-2 agents within one month prior to Day 1 (for Part 1) or prior to the randomization visit (Part 3).

      Exclusion Criteria for Either Eye

      • CNV due to causes other than nAMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, uveitis or central serous chorioretinopathy.
      • Prior participation in a clinical trial involving anti-VEGF drugs within six months prior to the screening visit, other than ranibizumab, aflibercept, or faricimab.
      • Active intraocular inflammation (grade trace or above), infectious conjunctivitis, keratitis, scleritis, or endophthalmitis.
      • History of uveitis, including history of any intraocular inflammation following intravitreal anti-VEGFor anti-VEGF/Ang-2 injections.
      • Prior treatment with brolucizumab.
      • Prior gene therapy for nAMD

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now